Trials / Conditions / Gastro-enteropancreatic Neuroendocrine Tumor

Gastro-enteropancreatic Neuroendocrine Tumor

11 registered clinical trials studyying Gastro-enteropancreatic Neuroendocrine Tumor.

Status	Trial	Sponsor	Phase
Completed	A Study to Understand Participant's Experiences in Gastro-enteropancreatic Neuroendocrine Tumors (GEP-NETs) an NCT06253897	Ipsen	—
Withdrawn	A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine NCT04614766	David Bushnell	Phase 1 / Phase 2
Active Not Recruiting	A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET NCT05050942	Camurus AB	Phase 3
Active Not Recruiting	Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET NCT03972488	Advanced Accelerator Applications	Phase 3
Active Not Recruiting	Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors NCT03600233	TaiRx, Inc.	Phase 2
Unknown	A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors NCT03475953	Institut Bergonié	Phase 1 / Phase 2
Completed	To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects NCT03220217	Ipsen	Phase 2
Unknown	The Lyon Real World Evidence in Metastatic NeuroEndocrine Tumours NCT03863106	Hospices Civils de Lyon	—
Terminated	FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas NCT03042780	H. Lee Moffitt Cancer Center and Research Institute	Phase 2
Withdrawn	Pasireotide Treatment for Neuroendocrine Tumor NCT02779257	University of Maryland, Baltimore	Phase 4
Completed	The Reproducibility Of Diffusion Weighted Magnetic Resonance Imaging For Neuroendocrine Tumor Liver Metastases NCT01423734	Memorial Sloan Kettering Cancer Center	—